���发背景与监管地位 — Common Mistakes

By Editorial Desk · published 2026-08-01 · last reviewed 2026-08-01 · Info

ACTH fragment comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.

研发背景与监管地位

当时的短肽研究普遍关注能否穿越血脑屏障、在低剂量下产生中枢效应，Semax 属于这一路线。鼻内给药是其主要使用方式，俄语文献报道的适应症涵盖缺血性卒中、短暂性脑缺血发作、认知功能减退以及视神经病变。这些研究大多发表在当地期刊上，样本规模与终点设置同西方试验惯例存在差异，国际同行对其临床证据的强度看法不一。

各国监管态度分化明显。俄罗斯按处方药管理，部分东欧国家留有使用记录；欧盟与美国未批准其作为药物上市，市面流通品通常标注为研究用化学品。身份差异意味着标示含量、纯度与无菌性缺少统一核查。体育领域还牵涉反兴奋剂名录，跨境携带则受目的地药品法规约束。

Semax Peptide Structure and Origin

Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its design combines the ACTH(4-7) core fragment with a C-terminal Pro-Gly-Pro extension, a modification intended to improve stability and prolong activity. The molecule is hydrophilic, carries no lipid chains or glycosylation, and has a theoretical mass just over 810 daltons in its free form. All seven residues are proteinogenic amino acids, so no non-natural building blocks appear in the backbone. A free N-terminal methionine and C-terminal proline define the unmodified parent peptide.

The compound was developed during the 1980s at the Institute of Molecular Genetics in Moscow as part of research on fragments of adrenocorticotropic hormone. Early work examined short ACTH-derived sequences that retained neurotrophic effects while lacking the endocrine activity of the full hormone. Semax entered clinical use in Russia during the 1990s, where it received registration for several neurological indications. Outside that region it remained primarily a laboratory research material rather than an approved therapeutic. English-language literature on it grew more slowly and frequently cited the original Russian studies.

Terminology around the compound varies by source. It appears in catalogues and papers as Semax, as the heptapeptide ACTH(4-7)-Pro-Gly-Pro, and under various alphanumeric laboratory codes used by individual suppliers. These names refer to the same sequence but may imply different salt forms, purity grades, or counter-ions. Peptide databases usually list the free base mass, while product descriptions sometimes report acetate or trifluoroacetate salts with a different formula weight. Because naming conventions for research peptides are not standardised across vendors, checking the declared sequence and measured mass is more reliable than relying on a trade name alone.

Semax at a glance

Semax Background And Mechanism

Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It was derived from the ACTH(4-10) fragment, a short segment of adrenocorticotropic hormone that lacks the hormonal activity associated with the full-length peptide. Researchers at the Institute of Molecular Genetics in Moscow developed the compound during the 1980s. It has been registered as a pharmaceutical product in Russia and several neighbouring countries, where it is supplied as a nasal solution, and it is also sold internationally as a research chemical.

The proposed mechanism centres on neurotrophic signalling rather than direct receptor activation. Semax is reported to increase expression of brain-derived neurotrophic factor and nerve growth factor in several brain regions, and to shift the balance between excitatory and inhibitory neurotransmitter systems. Interaction with melanocortin receptors has been suggested because of the parent ACTH fragment. Many of these findings come from rodent studies, and the extent to which they translate to human physiology remains an open question.

Scientific literature on semax is unevenly distributed. A substantial share of published work originates from a small number of laboratories in Russia, while independent replication elsewhere is limited. Human data consist mostly of small trials with short follow-up, and several reported outcomes rely on subjective rating scales. Questions about how much intact peptide reaches the central nervous system after nasal administration, and how long it persists there, are still unresolved. The compound is best described as an active research subject rather than a settled pharmacological agent.

Related pages on this site

• Measured summary
• Lightweight checklist
• Tracked notes
• Adaptive toolkit
• Tracked toolkit
• Practical briefing
• Material dataset
• Proven summary

Background and Development

Semax is a synthetic heptapeptide developed in the Soviet Union during the 1980s by researchers at the Institute of Molecular Genetics in Moscow. It was designed as a truncated analog of adrenocorticotropic hormone, retaining only the fragment spanning residues four through ten. Investigators sought a peptide that would preserve the cognitive effects associated with ACTH while eliminating the hormonal stimulation of the adrenal cortex. The compound entered clinical use in Russia during the following decade.

Russian regulatory authorities approved the peptide for nasal administration, and it remains listed in the national pharmacopoeia under several trade names. Documented indications include acute ischemic stroke, transient ischemic attacks, traumatic brain injury, and certain ophthalmological and neurological conditions. Physicians also prescribe it for cognitive complaints in older patients, although the evidence base for that use is thinner. Outside Russia and a few neighboring states, the substance is not an approved medicine and is sold instead as a research chemical.

Reference notes

=== Thermoregulation === Blood circulation transports heat throughout the body, and adjustments to this flow are an important part of thermoregulation. Increasing blood flow to the surface (e.g., during warm weather or strenuous exercise) causes warmer skin, resulting in faster heat loss. In contrast, when the external temperature is low, blood flow to the extremities and surface of the skin is reduced to prevent heat loss and is circulated to the important organs of the body, preferentially.

=== Cranial electrotherapy stimulation === A 2014 Cochrane review found insufficient evidence to determine whether or not Cranial electrotherapy stimulation with alternating current is safe and effective for treating depression.

=== Metabolism === Strychnine is rapidly metabolized by the liver microsomal enzyme system requiring NADPH and O2. Strychnine competes with the inhibitory neurotransmitter glycine resulting in an excitatory state. However, the toxicokinetics after overdose have not been well described. In most severe cases of strychnine poisoning, the patient dies before reaching the hospital. The biological half-life of strychnine is about 10 hours.

Sources: en.wikipedia.org

Notes from published material

== Appearances == Half-Life opens on Gordon Freeman as a research assistant at the Anomalous Materials wing of the Black Mesa Research Facility. After donning the Hazardous Environment suit for an experiment, Freeman survives an interdimensional "resonance cascade", taking up a crowbar as his signature weapon and fighting his way across the facility against both extradimensional invaders and hostile US marines to seal the rift. In Half-Life 2, after being kept in stasis for nearly two decades, Freeman battles the Combine Empire to liberate Earth. He gains legendary status as part of the resistance against the Combine forces and sparks a rebellion, ultimately destroying the Citadel, a major Combine stronghold. The G-Man rescues Freeman after this critical event, praising his accomplishments and placing him back in stasis. In Episode One, Gordon Freeman and Alyx Vance work to stabilize the Citadel's core to prevent a catastrophic explosion. In Episode Two, they work together to transport crucial data to close a forming super portal. After a revelation from the G-Man about saving Alyx, they learn about the Borealis, a research vessel with the potential to cause significant events. The game ends with Alyx mourning her father's death at the hands of a Combine Advisor. Half-Life: Alyx, set five years before Half-Life 2, follows Alyx Vance trying to locate Gordon. She infiltrates a Combine vault, believing it holds Gordon, but instead releases the G-Man.

The Harry Benjamin International Gender Dysphoria Association (HBIGDA), now known as the World Professional Association for Transgender Health (WPATH), was formed in 1979, with the first version of the Standards of Care published the same year. The Endocrine Society published guidelines for the hormonal care of transgender people in 2009, with a revised version in 2017. Hormone therapy for transgender women was initially done using high-dose estrogen therapy with oral estrogens such as conjugated estrogens, ethinylestradiol, and diethylstilbestrol and with parenteral estrogens such as estradiol benzoate, estradiol valerate, estradiol cypionate, and estradiol undecylate. Progestogens, such as hydroxyprogesterone caproate, medroxyprogesterone acetate, and other progestins, were also sometimes included. The antiandrogen and progestogen cyproterone acetate was first used in transgender women by 1977. Its use was standard at the Center of Expertise on Gender Dysphoria (CEGD; Kennis- en Zorgcentrum Genderdysforie, or KZcG) in Amsterdam, the Netherlands by 1985. Spironolactone, another antiandrogen, was first used in transgender women by 1986. These agents were described as allowing the use of much lower doses of estrogen than previously required, and this was considered advantageous due to risks of high doses of estrogens such as cardiovascular complications. Antiandrogens were well-established in hormone therapy for transgender women by the early 1990s. Estrogen doses in transgender women were reduced following the introduction of antiandrogens.

the Don Cossack Host the Bug Cossacks the Kuban Cossack Host the Terek Cossack Host the Astrakhan Cossack Host the Ural Cossack Host the Orenburg Cossack Host the Siberian Cossacks the Semiryechye Cossack Host the Transbaikal Cossack Host the Amur Cossack Host the Ussuri Cossack Host There was also a small number of the Cossacks in Krasnoyarsk and Irkutsk, who would form the Yenisey Cossack Host and the Irkutsk Cossack Regiment of the Ministry of the Interior in 1917. Cossack hosts on Russian soil were disbanded in 1920, in the course of the Russian Civil War of 1917–1922 in a deliberate process of De-Cossackization to remove their autonomy.

Sources: en.wikipedia.org

Frequently asked questions